{
    "nct_id": "NCT03927885",
    "official_title": "Open Labeled Placebo for Treatment of Cancer Related Fatigue in Patients With Advanced Cancer",
    "inclusion_criteria": "* Patient with a diagnosis of advanced cancer (metastatic or recurrent incurable solid tumors)\n* Presence of fatigue of >= 4/10 on Edmonton Symptom Assessment System (ESAS) Fatigue item (0-10 severity scale)\n* Patient should describe fatigue as being present for a minimum of 2 weeks prior to screening\n* Uncontrolled pain; patient is on opioids for the treatment of cancer pain, he/she must have had no major dose change (> 25%) for at least 48 hours prior to study entry. Change in opioid dose after study entry is allowed\n* Patient must be 18 years of age or older. The questionnaires used in this study have been validated only in the adult population\n* Patient must be willing to engage in telephone follow up with research staff\n* Patient must have telephone access to be contacted by the research staff\n* Hemoglobin level of >= 8 g/dL. Patient may receive packed red blood cell (PRBC) transfusion so as to have hemoglobin level of >= 8 g/dL so at participate in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Surgery, or pain relieving procedures within 2 weeks of entry into the study or during the study period\n* Patients with history of substance abuse (Cut down, Annoyed, Guilty, Eye opener [CAGE] >= 2+), cognitively impaired (MD Anderson Symptom [MDAS] > 7)",
    "miscellaneous_criteria": ""
}